Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

8 Feb 2011
Researchers identify enzyme that protects against inflammation, joint destruction

Researchers identify enzyme that protects against inflammation, joint destruction

8 Feb 2011
Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

5 Feb 2011
Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

5 Feb 2011
ACR releases two new provisional definitions of rheumatoid arthritis remission

ACR releases two new provisional definitions of rheumatoid arthritis remission

4 Feb 2011
Positive results from Factor IX-CTP comparative study in hemophilic mice

Positive results from Factor IX-CTP comparative study in hemophilic mice

3 Feb 2011
Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

2 Feb 2011
Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

2 Feb 2011
Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

31 Jan 2011
Adeona to sell 2.85 million common stock at $1.40 per share

Adeona to sell 2.85 million common stock at $1.40 per share

29 Jan 2011
Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

29 Jan 2011
Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

28 Jan 2011
Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

28 Jan 2011
Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

27 Jan 2011
DMP1 protein prevents endothelial cells to respond to VEGF

DMP1 protein prevents endothelial cells to respond to VEGF

27 Jan 2011
Research finds link between increased hygiene and higher rates of certain diseases in women

Research finds link between increased hygiene and higher rates of certain diseases in women

27 Jan 2011
Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

27 Jan 2011
Study: Low SES is linked to high risk of depression in patients with RA

Study: Low SES is linked to high risk of depression in patients with RA

26 Jan 2011
ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

26 Jan 2011
Ligand announces acquisition of CyDex Pharmaceuticals

Ligand announces acquisition of CyDex Pharmaceuticals

26 Jan 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback